Research Article
Treatment Resistance to TNF-α Inhibitors in Patients with Psoriasis
Table 1
The initial and demographic characteristics of the patients.
| | Characteristic | Patients with psoriasis (n = 131) |
| | Age (years; mean (SD)) | 45.06 (13.07) | | BMI (kg/m2; mean (SD)) | 31.11 (3.21) | | Sex (n (%)) | | Male | 71 (54.2%) | | Female | 60 (45.8%) | | Smoking (n (%)) | 42 (32.1%) | | PASI (mean (SD)) | 13.49 (5.19) | | Disease duration (months; mean (SD)) | 185.68 (105.20) | | Diagnosis to treatment duration (months; mean (SD)) | 35.39 (31.77) | | Previous treatments (n (%)) | | Topical | 22 (16.8%) | | Whole-body phototherapy | 7 (5.3%) | | Cyclosporine | 14 (10.7%) | | MTX | 79 (60.3%) | | Retinoid | 4 (3.1%) | | Anti-TNF-α | 5 (3.9%) | | Current biologic treatments (n (%)) | | Infliximab | 8 (6.1%) | | Adalimumab | 116 (88.5%) | | Etanercept | 7 (5.3%) | | Duration of the current treatment (months; mean (SD)) | 19.16 (15.11) | | Recalcitrant disease (n (%)) | 77 (58.8%) | | Psoriatic arthritis (n (%)) | 39 (29.8%) |
|
|
SD: standard deviation; PASI: psoriasis area severity index; MTX: methotrexate.
|
